Use of potassium tellurite for rapid-drug susceptibility testing of Mycobacterium avium complex

被引:4
作者
Afghani, B
Fujiyama, D
机构
[1] Miller Childrens Hosp, Dept Pediat Infect Dis, Long Beach, CA 90801 USA
[2] Calif State Univ Long Beach, Long Beach, CA 90840 USA
[3] Univ Calif Irvine, Irvine, CA USA
关键词
mycobacterium avium; tellurite; susceptibility; testing minimum inhibitory concentration; clarithromycin;
D O I
10.2310/6650.2001.33975
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Mycobacterium avium complex (MAC) is a major cause of infection in immunocompromised patients. MAC possesses an enzyme that reduces potassium tellurite in less than 3 days and results in formation of a black precipitate. The objective of this study was to determine whether reduction of potassium tellurite by mycobacteria can be used as a means of testing the susceptibility of MAC to clarithromycin. Methods: Minimum inhibitory concentrations (MICs) for 104 clinical isolates of MAC were determined bg the tellurite method and compared with those tested by a recommended microdilution method. Microdilution breakpoints mere used for interpretation of susceptibility. MIC of less than 8 mug/mL was considered as susceptible, and MIC of greater than or equal to 8 mug/mL. was resistant. Results: There was agreement within a 2-fold dilution between MICs for 89% of isolates. Of the 53 isolates that had discrepant MICs by the two methods, 70% had higher MICs by the tellurite method. When the MICs were classified into interpretive categories, there was 100% agreement by the two methods. The MI6 tested by the tellurite method was available within 5 days, Conclusions: These data suggest that use of potassium tellurite is a more rapid, reliable, and inexpensive method of testing the susceptibility of MAC to clarithromycin.
引用
收藏
页码:292 / 296
页数:5
相关论文
共 15 条
[1]  
AFGHANI B, 1996, 36 INT C ANT AG CHEM
[2]   ISOLATION OF MYCOBACTERIUM-AVIUM COMPLEX FROM BONE-MARROW ASPIRATES OF AIDS PATIENTS IN BRAZIL [J].
BARRETO, JA ;
PALACI, M ;
FERRAZOLI, L ;
MARTINS, MC ;
SULEIMAN, J ;
LORENCO, R ;
FERREIRA, OC ;
RILEY, LW ;
JOHNSON, WD ;
GALVAO, PAA .
JOURNAL OF INFECTIOUS DISEASES, 1993, 168 (03) :777-779
[3]   CLARITHROMYCIN THERAPY FOR BACTEREMIC MYCOBACTERIUM-AVIUM COMPLEX DISEASE - A RANDOMIZED, DOUBLE-BLIND, DOSE-RANGING STUDY IN PATIENTS WITH AIDS [J].
CHAISSON, RE ;
BENSON, CA ;
DUBE, MP ;
HEIFETS, LB ;
KORVICK, JA ;
ELKIN, S ;
SMITH, T ;
CRAFT, JC ;
SATTLER, FR ;
STOOL, EW ;
MACGREGOR, RR ;
BUEHNER, T ;
WU, AW ;
BARNES, GL ;
BECKER, R ;
URBANSKI, P ;
RICHARDSON, W ;
HAFNER, R ;
DIXON, D ;
FEIGAL, DW ;
DELLERSON, M ;
GUPTA, S ;
HENRY, D ;
SCHLAGER, S .
ANNALS OF INTERNAL MEDICINE, 1994, 121 (12) :905-911
[4]   CLARITHROMYCIN AND OTHER ANTIMICROBIAL AGENTS IN THE TREATMENT OF DISSEMINATED MYCOBACTERIUM-AVIUM INFECTIONS IN PATIENTS WITH ACQUIRED-IMMUNODEFICIENCY-SYNDROME [J].
DAUTZENBERG, B ;
SAINTMARC, T ;
MEYOHAS, MC ;
ELIASZEWITCH, M ;
HANIEZ, F ;
ROGUES, AM ;
DEWIT, S ;
COTTE, L ;
CHAUVIN, JP ;
GROSSET, J .
ARCHIVES OF INTERNAL MEDICINE, 1993, 153 (03) :368-372
[5]   Susceptibility testing of Mycobacterium avium complex isolates [J].
Heifets, L .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (08) :1759-1767
[6]  
HEIFETS L, 1993, ANTIMICROB AGENTS CH, V37, P3264
[7]   CLARITHROMYCIN MINIMAL INHIBITORY AND BACTERICIDAL CONCENTRATIONS AGAINST MYCOBACTERIUM-AVIUM [J].
HEIFETS, LB ;
LINDHOLMLEVY, PJ ;
COMSTOCK, RD .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1992, 145 (04) :856-858
[8]  
HEIFETS LB, 1985, ANTIMICROB AGENTS CH, V28, P570, DOI 10.1128/AAC.28.4.570
[9]   CURRENT CONCEPTS - MYCOBACTERIUM-AVIUM COMPLEX INFECTION IN THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME [J].
HORSBURGH, CR .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (19) :1332-1338
[10]  
Kent P. T., 1985, PUBLIC HLTH MYCOBACT